Why is the approval of Truvada for prevention so significant for Kenya? According Kenya AIDS Indicator Survey of 2012, serodiscordant couples contribute 44% of all new infections, while men who have sex with men and female sex workers contribute a third. HIV prevalence is highest in the population 20-29 years, and young women 20-24 years are four times more likely to be HIV positive compared with young men the same age. The recent approval by the Kenya Pharmacy and Poisons Board of the drug Truvada for prevention of HIV by uninfected persons deemed at risk — pre-exposure prophylaxis (PrPEP) — reflects commitment from the regulatory authority to fast-track the review of drugs of public health importance.
Read more here.